Skip to main content

Advertisement

Table 1 Demographic, clinical and biological characteristics of patients enrolled in the first study

From: Local hyperhemia to heating is impaired in secondary Raynaud's phenomenon

  Healthy controls (n = 20) Primary RP (n = 20) SSc (n = 20)
Age (years) 47 (37–58) 46 (37–59) 50 (33–61)
Female 18 (90%) 18 (90%) 18 (90%)
Body mass index (kg/m2) 22 (20–29) 20 (18–23) 23 (20–26)
Raynaud's phenomenon 0 20 (100%) 20 (100%)
   Median Raynaud's disease duration (years) 0 18 (6–43) 8 (3–22)
   Raynaud's phenomenon: median number of fingers involved 0 8 (6–10) 10 (8–10)
   Raynaud's phenomenon: thumb involved 0 7 (35%) 18 (90%)
   Raynaud's phenomenon: feet involved 0 8 (40%) 16 (80%)
Median disease duration (years) NA NA 5 (0,5–16)
Digital pitting scars 0 0 8 (40%)
Sclerodactyly 0 0 20 (100%)
Median Rodnan modified skin score 0 0 6 (2–29)a
dcSSc/lcSSc 0/0 0/0 6/14
Pulmonary fibrosis 0 0 7 (35%)
Esophageal dysmotility 0 0 13 (65%)
Median creatinine clearance (ml/min) 81.7 (66–119) 74.9 (68–97) 87.9 (79–139)
Microalbuminuria (mg/l) 11 (11–17.6) 11 (11–20.8) 11 (11–17.7)
Median cardiac rate (beat/min) 62 (49–77) 69 (52–92) 65 (57–78)
Median systolic/diastolic blood pressure (mm Hg) 111 (99–133)/ 66 (54–78) 107 (91–122)/ 62 (52–79) 106 (89–141)/ 67 (54–85)
Median oxygen saturation (%) 99 (97–100) 100 (97–100) 100 (96–100)
Autoantibodies    
   Anti-centromere 0 0 8 (40%)
   Anti-topoisomerase I 0 0 5 (25%)
Median plasma LDL cholesterol (g/l) 1.04 (0.7–1.4) 1.04 (0.6–1.4) 0.9 (0.6–1.2)
Median plasma triglycerides (g/l) 0.7 (0.3–1) 0.5 (0.4–0.9) 0.7 (0.3–0.9)
Median plasma glycemia (mmol/l) 4.7 (3.6–5.3) 4.6 (4–5.7) 4.6 (4.3–5.2)
  1. Quantitative data are medians, with 10th and 90th percentiles in parentheses. Qualitative data are expressed as numbers. aThe median Rodnan modified skin score was 4 (2–11) for the limited cutaneous systemic sclerosis (lcSSc) and 25 (12–43) for the diffuse cutaneous systemic sclerosis (dcSSc). NA, not applicable.